Table 1. Patient Characteristics.
Interquartile range (IQR), Body mass index (BMI), Recipient (R), Donor (D), Cytomegalovirus (CMV), Acute lymphoblastic leukemia (ALL), Total body irradiation (TBI), Graft versus host disease (GVHD), Antithymocyte globulin (ATG), Peripheral blood (PB), Bone marrow (BM)
| Value | N | Missing, n | |
|---|---|---|---|
| Median year (IQR) | 2009 (2007–2011) | 25923 | 0 |
| Median recipient age (IQR) | 45 (33–56) | 25923 | 0 |
| Median BMI (IQR) | 24 (22–27) | 9350 | 16573 |
| Median days between diagnosis and HSCT (IQR) | 191 (138–363) | 25914 | 9 |
| Median donor's age (IQR) | 38.8 (29–48) | 10027 | 15896 |
| Recipient gender | 25872 | 51 | |
| Male | 14228 (55.0%) | ||
| Female | 11644 (45.0%) | ||
| Recipient CMV serostatus | 22855 | 3068 | |
| - | 7788 (34.1%) | ||
| + | 15067 (65.9%) | ||
| Karnofsky at transplant | 24369 | 1554 | |
| > = 80 | 22966 (94.2%) | ||
| <80 | 1403 (5.8%) | ||
| Comorbidity score merged | 2469 | 23454 | |
| 0 | 403 (16.3%) | ||
| 1 | 747 (30.3%) | ||
| 2 | 457 (18.5%) | ||
| 3 | 419 (17.0%) | ||
| > = 4 | 443 (17.9%) | ||
| Diagnosis | 25923 | 0 | |
| AML | 18610 (71.8%) | ||
| ALL | 7313 (28.2%) | ||
| Cytogenetics risk | 13430 | 12493 | |
| Standard | 10080 (75.1%) | ||
| Poor | 3350 (24.9%) | ||
| Disease stage | 25923 | 0 | |
| CR1 | 16201 (62.5%) | ||
| CR2 | 4909 (18.9%) | ||
| Advanced | 4813 (18.6%) | ||
| Previous autograft | 25923 | 0 | |
| - | 25235 (97.3%) | ||
| + | 688 (2.7%) | ||
| Donor gender | 25357 | 566 | |
| Male | 15712 (62.0%) | ||
| Female | 9645 (38.0%) | ||
| Donor CMV serostatus | 22726 | 3197 | |
| - | 10927 (48.1%) | ||
| + | 11799 (51.9%) | ||
| D-R sex combination | 25318 | 605 | |
| Male D to male R | 9153 (36.2%) | ||
| Female D to female R | 4863 (19.2%) | ||
| Male D to female R | 6528 (25.8%) | ||
| Female D to male R | 4774 (18.9%) | ||
| D-R CMV serostatus combination | 22395 | 3528 | |
| D-CMV–/R-CMV– | 5572 (24.9%) | ||
| D-CMV+/R-CMV–or D-CMV–/R-CMV+ | 8917 (39.8%) | ||
| D-CMV+/R-CMV+ | 7906 (35.3%) | ||
| Donor type | 25923 | 0 | |
| HLA matched unrelated donor | 13585 (52.4%) | ||
| HLA identical sibling | 12338 (47.6%) | ||
| HLA match degree | 9090 | 16833 | |
| 10/10 | 6519 (71.7%) | ||
| 9/10 | 2068 (22.8%) | ||
| <9/10 | 503 (5.5%) | ||
| Source of stem cells | 25923 | 0 | |
| BM | 4109 (15.9%) | ||
| PB or BM+PB | 21814 (84.1%) | ||
| Conditioning | 25420 | 503 | |
| MAC | 16836 (66.2%) | ||
| RIC | 8584 (33.8%) | ||
| TBI | 25742 | 181 | |
| No | 15042 (58.4%) | ||
| Yes | 10700 (41.6%) | ||
| GVHD prevention | 23228 | 2695 | |
| Ex-vivo T cell depletion | 800 (3.4%) | ||
| In-vivo T cell depletion | 9825 (42.3%) | ||
| No T cell depletion | 12603 (54.3%) | ||
| Relapse at day 100 | 25923 | 0 | |
| - | 23384 (90.2%) | ||
| + | 2539 (9.8%) | ||
| Non relapse related mortality at day 100 | 25923 | 0 | |
| - | 23536 (90.8%) | ||
| + | 2387 (9.2%) | ||
| Overall mortality at day 100 | 25923 | 0 | |
| - | 22643 (87.3%) | ||
| + | 3280 (12.7%) |